Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Vomiting 3Nausea 2Anorexia 2Weight Loss 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Opioid-Related Disorders 1Muscular Atrophy 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Gynecologic Cancer 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Child Nutrition Disorders 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1

Interventions

anamorelin 2Caloric Restriction 2Urine Specimen Collection 1Tirzepatide 1Sampling Studies 1Resistance Training 1Psychology, Positive 1Population Groups 1Olanzapine 1Nutrition Assessment 1Mirtazapine 1Methods 1Metformin 1Megestrol Acetate 1Inositol 1Growth Differentiation Factor 15 1Diet, Reducing 1Diet Therapy 1Diet 1Counseling 1Cognitive Behavioral Therapy 1Breast Implants 1Blood Specimen Collection 1Biopsy 12,2,2',4'-tetrachloroacetophenone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Weight Loss × Olanzapine × 1 year × Clear all
NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡